Large NHS Galleri Blood Screening Trial Misses Primary Endpoint, Setback for Liquid Biopsy Mass Screening Prospects

The large UK NHS-Galleri randomized trial has suffered a key setback. According to The Guardian, the study, which enrolled about 142,000 NHS participants, failed to meet its primary objective: proving that adding Grail’s Galleri multi-cancer early detection blood test to standard cancer screening could produce a statistically significant decline in late-stage cancer diagnoses.

Galleri is one of the “liquid biopsy” applications that has drawn considerable attention in recent years. Its goal is to detect multiple types of as-yet undiagnosed cancer through cancer-related signals in the blood. If tumors can be found before symptoms or imaging abnormalities appear, it could theoretically improve opportunities for early treatment and may also help address the limitation that current screening covers only some cancer types.

However, the threshold for population screening differs from simply showing whether a testing technology can find cancer. Large public health programs must prove that a test can improve clinical outcomes, such as reducing late-stage diagnoses and lowering mortality, while avoiding excessive false positives, overdiagnosis, anxiety, and the burden of follow-up testing. The failure to meet the primary endpoint means the evidence base for Galleri as a tool for broad NHS adoption remains insufficient.

The report said the trial still showed some secondary signals, but these need to be interpreted cautiously given the failure of the primary endpoint. Secondary analyses may help clarify which cancer types, which groups, or which clinical settings are more likely to benefit, but they are usually not enough on their own to support large-scale screening policy.

The result also highlights the central challenge in the field of multi-cancer early detection: whether a test can change the course of disease in real-world healthcare systems, rather than merely finding disease earlier. For some cancers that progress slowly or have limited treatment options, earlier diagnosis may not automatically translate into a better prognosis; for healthcare systems under strain, capacity for imaging, endoscopy, or specialist referrals after a positive result is also important.

Currently available information remains limited, and observers still need to wait for the full study data and peer-reviewed analysis before judging whether the trial design, participants’ risk distribution, adherence, cancer-type-specific performance, and follow-up duration affected the results. For patients, this also does not mean that all blood-based cancer tests are ineffective, but rather that using a single multi-cancer blood test for large-scale screening of the general population has not yet crossed a key evidentiary threshold.

For the liquid biopsy industry, the NHS-Galleri trial is an important warning sign. Future research and development may shift toward more clearly defined high-risk groups, use cases that complement existing screening pathways, and long-term studies that directly measure mortality, the proportion of late-stage cancers, and healthcare burden, rather than relying only on early detection rates as the main selling point.